Evaluation of the activity of trans-Resveratrol alone and in combination with Amlodipine and Pioglitazone against Fructose induced metabolic syndrome rats

Abstract

Metabolic syndrome (MS) is a cluster of conditions that cause an increase in the risk of diabetes, heart disorders, and stroke.The present research was completed in Wistar rats, in which Metabolic Syndrome (MS) was induced with a High Fructose Diet. Animals were randomly divided into 7 gatherings and the test group animals received Resveratrol (RSVT), Amlodipine (AML), Pioglitazone (PIO), Resveratrol+Amoldipine, and Resveratrol+Pioglitazone at different doses for 5 weeks. Various behavioral, biochemical, and histopathological parameters were estimated.AML alone and along with RSVT was found to reduce diastolic and systolic pressures, there was the reduction in BP in the remaining groups. There was a significant reduction in serum insulin and Fasting glucose level (FGL) in all the treatment groups. And there was a noticeable reduction in the levels of total glycerides (TG), total cholesterol (TC) along with LDL, HDL, and VLDL when compared to the control group and HFD group. Histopathological study revealed that there was a reduction in the deposition of lipids in liver cells and aorta as compared to HFD group.The outcomes showed the defensive mechanism of Resveratrol against fructose-induced Metabolic Syndrome. The mechanism of protection may be due to an escalation of cellular antioxidants. The activity was found to increase in combination with amlodipine and pioglitazone.